Insilico’s $2.5b AI drug discovery deal targets neuroimmune failure

Partnership with SK Biopharma signals growing confidence that AI can accelerate search for treatments for some of brain’s toughest diseases. For all the excitement surrounding AI, one question still hangs over the biotechnology sector: can AI actually help deliver better medicines? A new collaborati…

View Post on Scour ↗

More from longevity.technology on Scour.